ArticleJournal of gastroenterology and hepatology2026
Preventive Effect of Helicobacter pylori Treatment on Colorectal Cancer Incidence and Mortality.
Article in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
aimMany studies have reported an association between Helicobacter pylori infection and an increased risk of colorectal cancer (CRC); however, the impact of eradication therapy on CRC remains unclear. We compared CRC incidence and mortality in individuals who received H. pylori treatment with those in the general population.
methodsWe conducted a population-based study of 931 585 participants aged ≥ 20 years who received H. pylori eradication (HPE) therapy between 2009 and 2011. We used the one-sample log-rank test to compare standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) for CRC.
resultsThe mean follow-up period was 12.4 ± 1.1 years. CRC incidence and mortality rates were significantly lower in H. pylori-treated individuals than in the general population (total SIR: 0.66, 95% confidence intervals [CI] 0.64-0.67 and SMR: 0.51, 95% CI 0.49-0.54). Significant results were also observed in the 30-39, 40-49, 50-59, 60-69, and ≥ 70 age groups: The SIRs (95% CIs) were 0.80 (0.71-0.89), 0.73 (0.70-0.77), 0.62 (0.60-0.65), 0.66 (0.63-0.68), and 0.62 (0.59-0.66), respectively, and the SMRs (95% CIs) were 0.53 (0.36-0.76), 0.46 (0.39-0.54), 0.41 (0.37-0.46), 0.48 (0.44-0.53), and 0.65 (0.60-0.71), respectively. Similar results were observed when colon and rectal cancer were analyzed separately.
conclusionsHPE may help reduce the risk and improve the survival from CRC. Its benefits may extend beyond preventing gastric cancer to CRC prevention. Our findings support the need for aggressive H. pylori screening and eradication treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.